Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Screening for High Frequency Malignant Disease

NCT: NCT05117840 · ACTIVE_NOT_RECRUITING

NCT IDNCT05117840
StatusACTIVE_NOT_RECRUITING
Start Date2022-01-13
Completion2026-12-31
SponsorGuardant Health, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑